December 15, 2021
Press & Media
PlexBio Gets CE Mark for PCR-based Coronavirus Detection Kit
2020.05.05
NEW YORK ─ Taipei, Taiwan-based PlexBio said Monday that it has received the CE mark for its IntelliPlex SARS-CoV-2 Detection Kit and the test is now available in European countries.
This PCR-based test detects SARS-CoV-2 in nasopharyngeal swab specimens from patients who may or may not exhibit symptoms of COVID-19, the firm said.
PlexBio added that its test runs on its IntelliPlex platform for multiplex assays and can process up to 564 samples within eight hours. The kit leverages the multiplexing capabilities of the IntelliPlex platform by simultaneously detecting the E, N, and RdRp genes in the virus, which mitigates the probability of getting false negative results, the firm said.
For complete news, please visit genomeweb.
NEW YORK ─ Taipei, Taiwan-based PlexBio said Monday that it has received the CE mark for its IntelliPlex SARS-CoV-2 Detection Kit and the test is now available in European countries.
This PCR-based test detects SARS-CoV-2 in nasopharyngeal swab specimens from patients who may or may not exhibit symptoms of COVID-19, the firm said.
PlexBio added that its test runs on its IntelliPlex platform for multiplex assays and can process up to 564 samples within eight hours. The kit leverages the multiplexing capabilities of the IntelliPlex platform by simultaneously detecting the E, N, and RdRp genes in the virus, which mitigates the probability of getting false negative results, the firm said.
For complete news, please visit genomeweb.